We are pleased to be among the 30+ advanced therapy companies whose CEOs have joined the Alliance for Regenerative Medicine (ARM) in calling on EU leaders to take coherent and coordinated actions to secure Europe’s future in the cell and gene therapy space.
The joint letter, issued in June 2025, presents a policy blueprint to unlock the full potential of Advanced Therapy Medicinal Products (ATMPs) in Europe. It outlines four priority areas critical to driving innovation, improving patient access, and maintaining global competitiveness.
As one of the companies contributing to this shared vision, we support this initiative and its call for a European “streamlined, coherent, and flexible framework” to advanced therapies. We believe that by aligning science, industry, regulation, and policy can Europe truly translate its world-class capabilities into transformative outcomes for patients and society.
Read the full letter and policy recommendations here.
